Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus TRIACET.
BREO ELLIPTA vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid